MiMedx Group, Inc. (MDXG)

NASDAQ: MDXG · IEX Real-Time Price · USD
3.54
+0.06 (1.72%)
Jun 29, 2022 4:00 PM EDT - Market closed
1.72%
Market Cap 401.27M
Revenue (ttm) 257.54M
Net Income (ttm) -18.65M
Shares Out 113.35M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 248,267
Open 3.45
Previous Close 3.48
Day's Range 3.39 - 3.56
52-Week Range 3.04 - 15.99
Beta 1.92
Analysts Buy
Price Target 12.07 (+241.0%)
Earnings Date Aug 2, 2022

About MDXG

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of ch... [Read more...]

Industry Biotechnology
Employees 811
Stock Exchange NASDAQ
Ticker Symbol MDXG
Full Company Profile

Financial Performance

In 2021, MiMedx Group's revenue was $258.62 million, an increase of 4.18% compared to the previous year's $248.23 million. Losses were -$16.42 million, -80.29% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for MDXG stock is "Buy." The 12-month stock price forecast is 12.07, which is an increase of 240.96% from the latest price.

Price Target
$12.07
(240.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injec...

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX's Knee Osteoarthritis Clinical Trial Program

Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change

Notes that a Majority of the Non-Affiliated, Non-Institutional Shares Voted Against the Re-Election of Incumbent Directors, and Against Approval of Executive Compensation Demands Leadership Immediately ...

MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors

Prescience Point Capital Management Calls On MiMedx Group to Immediately Release Preliminary Voting Results of its An...

Believes That a Massive Number of Shares Voted Against the Re-Election of Incumbent Directors and Against Approval of Executive Compensation BATON ROUGE, La. , June 7, 2022 /PRNewswire/ -- Prescience Po...

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

Deadline to Pre-Register is 9:00 a.m. Eastern Time on June 6, 2022

MIMEDX Addresses Presentation by Prescience Point

Company Highlights Factually Accurate Information Already Provided

MIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders

Urges Shareholders to Vote “FOR” MIMEDX's Highly Qualified and Independent Directors – James L. Bierman and Phyllis Gardner, M.D. on the WHITE Proxy Card Today

Prescience Point Capital Management Releases Presentation Detailing Board And Management Failures at MiMedx Group

Votes WITHHOLD against board directors Phyllis Gardner and James Bierman at 2022 Annual Meeting to send a message to MiMedx Demands Management and the Board Show Confidence in MiMedx and Alignment With ...

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds ...

Funding Enables Evaluation of PURION® Processed Placental Tissue as an Innovative Approach in the Management of Acute Military-Related Injuries, Addressing a Critical Unmet Need

Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company's Propo...

Follows Previous Recommendation from Glass Lewis in Support of ALL Proposals

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company...

Recommends Shareholders Vote “FOR” Both of MIMEDX's Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D.

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have  Established Strong, New Foundation for Growth

Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received Letters of Serious Concern fr...

Disappointed that the MiMedx Board Has Resorted to Disinformation and Distortions to Distract Shareholders from the Board's and Management's Own Failures Reiterates Intention to Withhold Votes Against D...

Prescience Point Capital Management Issues Open Letter to Shareholders of MiMedx Group

Intends on Withholding Votes Against Directors Phyllis Gardner and James Bierman at 2022 Annual Meeting and Vote Against Approval of Executive Compensation BATON ROUGE, La. , May 6, 2022 /PRNewswire/ --...

MIMEDX to Participate at Upcoming Investor Conferences

MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will...

MIMEDX Announces First Quarter 2022 Operating and Financial Results

First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of Products

MIMEDX Comments on Prescience Point's Recent Filing

Shareholders Urged to Support MIMEDX Board

MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4

MARIETTA, Ga., April 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report opera...

MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC ...

Company to Sponsor Symposium and Present Three Poster Abstracts

WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers Nationwide

TAMPA, Fla. , March 16, 2022 /PRNewswire/ -- Leading wound care management and clinical services provider, WoundGenex, today announced a strategic partnership with MiMedx Group, Inc. (Nasdaq: MDXG) ("MI...

MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference

MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, C...

MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Fourth Quarter Net Sales of $67.4 M illion and Full Year 2021 Net Sales of $258.6 M illion; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products

Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHA...

Use of MIMEDX PURION® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years

MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28

MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operat...

MIMEDX Announces Dismissal of Putative Securities Class Action Lawsuit

MARIETTA, Ga., Jan. 28, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that a federal court in Ge...